NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1α protein in human ovarian cancer cells
Introduction
Ovarian carcinoma is the seventh most common malignancy and the fifth leading cause of death from cancer in women [1], [2]. Due to the asymptomatic nature of early ovarian cancer, patients were diagnosed predominately at advanced stage [2], [3]. Primary treatment of ovarian cancer involves cytoreductive surgery and platinum-based combination chemotherapy, to which more than 80% of patients show an initial chemotherapeutic response. However, most women with advanced-stage disease at initial diagnosis will develop recurrent tumors that are resistant to traditional platinum-based therapy [4]. As documented, patients with ovarian cancer had a 5-year survival rate of less than 30% [3]. Therefore, it is imperative to continue exploring for novel therapies for ovarian cancer.
Camptothecin represents a promising new class of anticancer drugs, and have advanced to the forefront of several areas of therapeutic and developmental chemotherapy [5]. For example, topotecan, a water-soluble, semisynthetic analog of camptothecin, has been approved by the US Food and Drug Administration for the treatment of recurrent epithelial ovarian cancer and has demonstrated activity in both platinum – and paclitaxel-resistant ovarian cancer [6]. More recently, lower concentration (nanomolar, nM) of NSC606985, a highly water-soluble camptothecin analog [7], was reported to induce apoptosis in acute myeloid leukemia (AML) cells [8], and to present the potential therapeutic effects on the leukemic mice model [9]. Furthermore, NSC606985 was also shown to induce cell apoptosis and growth arrest in prostate tumor cells [10]. In this work, we attempted to explore the potential effects of NSC606985 and its combination with cisplatin (CDDP), a very well-established agent in the treatment of ovarian cancer [11], on ovarian cancer cells.
Section snippets
Cell treatment
Human ovarian cancer line COC1 was purchased from China Typical Culture Collection Center (Wuhan, China), and were cultured in RPMI-1640 medium (Sigma, St Louis, MO) supplemented with 10% heat-inactivated fetal calf serum (FCS; Hyclone, Logan, UT) in a 5% CO2 95% air humidified atmosphere at 37 °C. For experiments, cells were treated with the indicated concentrations of NSC606985 (kindly provided by National Cancer Institute Anticancer Drug Screen standard agent database, Bethesda, MD, and
NSC606985 induces apoptosis of human ovarian cancer COC1 cell line
To explore the effect of NSC606985 on human ovarian cancer cells, COC1 cells were treated with various concentrations (from 6.25 to 100 nM) of NSC606985 for the time period of 1 to 3 days, and cell growth was detected by MTT assay. The results showed that nM concentrations of NSC606985 induced growth inhibition in the time- and concentration-dependent manners (Fig. 1A). The estimated IC50 values for NSC606985 were 117.70, 29.73 and 19.27 nM for 24, 48 and 72 h treatments, respectively. To
Discussion
Camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, have become a rapidly growing family of anticancer agents. Especially, topotecan has been approved as a second-line therapy for ovarian cancer or small-cell lung cancer, and irinotecan for the treatment of colorectal carcinoma refractory to 5-fluorouracil or as initial therapy in combination with 5-flurouracil for the treatment of metastatic colorectal cancer [18]. In the past years, anti-leukemic and anti-prostate
Conflict of interest
None of the authors has any potential conflicts of interest.
Acknowledgements
We are grateful to Dr. Robert Schultz at Division of Cancer Treatment and Diagnosis, National Cancer Institute (Bethesda, MD) to provide us the NSC606985 compound. This work has been sponsored by grants from International Collaborative Items of Ministry of Science and Technology of China (2006DFA32780) and National Natural Science Foundation (30500257), Science and Technology Commission of Shanghai (08JC1413700). Dr. GQ Chen is a Chang Jiang Scholar of Ministry of Education of China, and is
References (34)
- et al.
The camptothecins
Lancet
(2003) - et al.
Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cdelta-dependent mechanisms
Blood
(2005) - et al.
Therapeutic efficacy of NSC606985, a novel camptothecin analog, in a mouse model of acute promyelocytic Leukemia
Leuk. Res.
(2007) - et al.
Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors
Adv. Enzyme Regul.
(1984) - et al.
Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells
Am. J. Pathol.
(2003) - et al.
Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells
J. Biol. Chem.
(2002) - et al.
Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma
Gynecol. Oncol.
(2007) Evaluation of HIF-1 inhibitors as anticancer agents
Drug Discov. Today
(2007)Update on the role of topotecan in the treatment of recurrent ovarian cancer
Oncologist
(2002)- et al.
Current concepts of treatment strategies in advanced or recurrent ovarian cancer
Oncology
(2005)
Advances in the management of epithelial ovarian cancer
J. Reprod. Med.
Standard treatment in advanced ovarian cancer in 2005: the state of the art
Int. J. Gynecol. Cancer
Review of the use of topotecan in ovarian carcinoma
Expert. Opin. Pharmacother.
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway
Cancer Res.
NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells
Cancer Chemother. Pharmacol.
New, expanded, and modified use of approved antineoplastic agents in ovarian cancer
Oncologist
Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design
J. Natl. Cancer Inst.
Cited by (17)
Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1α
2011, Cancer LettersCitation Excerpt :The α subunit of HIF-1 has been shown to be overexpressed in more than 70% of solid tumors [2] and contributes to chemoresistance in multiple malignancies [3–6]. Ovarian cancer is the seventh most common malignancy and the fifth leading cause of death from cancer in women [7]. First-line treatment based on platinum drugs and taxanes induces remission in over 80% of patients, but almost all ovarian cancers recur [8] and develop chemoresistance [9].
Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance
2023, Journal of Experimental and Clinical Cancer ResearchThe modulatory effect of green tea catechin on drug resistance in human ovarian cancer cells
2019, Medicinal Chemistry ResearchThe favourable effect of catechin in electrochemotherapy in human pancreatic cancer cells
2018, Acta Biochimica PolonicaDual action of NSC606985 on cell growth and apoptosis mediated through PKCδ in prostatic cancer cells
2017, International Journal of Oncology